3. Olga Potapova is a highly accomplished life sciences executive and a successful entrepreneur with extensive expertise in establishing preclinical, translational and precision medicine services since 2003. After working for a decade in academic research with novel programs in oncology, signal transduction, stress and aging (UCSD, SDRCC, NIA/NIH), she made significant contributions in developing targeted oncology translational projects at SUGEN (Pfizer). Currently Dr. Potapova is the CEO of the Cureline Group of companies, a global CRO providing services for drug R&D, precision medicine programs, and biomarker and companion diagnostics development. At Cureline she is responsible for global strategic development, international alliance management, and expansion into new markets. Olga has received multiple AACR/AFLAC awards, prestigious fellowships from the NIH and NATO, and published numerous scientific papers in peer-reviewed journals.  Since 2010, Dr. Potapova is a Principal Investigator for The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) programs (NCI, NIH). Dr. Potapova holds advanced degrees in Physics and Molecular Genetics/Biochemistry providing her with a strong multidisciplinary foundation in life sciences and translational medicine. 
4. Linkedin

Agne Vaitkeviciene holds a BS in Molecular Biology (Vilnius University, Lithuania) and an MS in organ, tissue, and cell donation for Cell Therapy (University of Barcelona, Spain). Since 2006 she has been working in the field of cell therapy and ATMP manufacturing under GMP conditions. In 2013 Agne Vaitkeviciene co-founded a life science startup company and managed its activities in the field of advanced therapy medicinal product (ATMP) research and manufacturing as CEO until 2019. Since 2019 she has been actively involved as an expert in EU programs, such as IMI2, EIT Health Innostarts, and consults biotechnology companies in life science product development management. For the last 5 years, Agne has been actively involved in life science expert groups within Lithuanian governmental organizations such as the Innovation Agency of Lithuania and Invest Lithuania. Association LithuaniaBIO elected Ms. Vaitkeviciene as a Vice-President in 2019 and delegated her responsibilities of coordinating foreign affairs and startup support activities within the Association. In 2020 - 2023 she was the Executive Director of LithuaniaBIO. In 2020 Agne joined Cureline Group as a COO of Cureline Baltic and later, together with Dr. Olga Potapova, founded Memel Biotech in 2021 in Klaipeda, Lithuania. Currently, Agne is responsible for overall Cureline Group activities in Lithuania, provides leadership for the ATMP CDMO program, and coordinates BD efforts in the EU region for member companies of the Cureline Group.

Linkedin